Smiths Detection’s BioFlash shown to detect airborne COVID-19
Smiths Detection, a global leader in threat detection and security screening technologies, today reports that its BioFlash® Biological Identifier is capable of detecting SARS-CoV-2 in the air following tests conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
The tests were performed using live SARS-CoV-2 virus in a Biosafety Level 3 containment area at Fort Detrick, Maryland. The SARS-CoV-2 CANARY biosensor used in the BioFlash device demonstrated that it can quickly detect and identify the presence of low levels of aerosolized SARS-CoV-2.
The BioFlash® Biological Identifier is powered by CANARY® technology (a cell-based biosensor) and is combined with proprietary aerosol-collection techniques to provide rapid, sensitive and specific identification of biological-threat agents including viruses, toxins and bacteria.
“We are working incredibly hard to provide a tool that will support the ongoing fight against the coronavirus,” said Roland Carter, President, Smiths Detection. “BioFlash is an effective and trusted environmental monitoring tool. These test results provide valuable data in understanding the spread of COVID-19 and help protect people in indoor environments such as hospitals, schools and commercial buildings.”
USAMRIID confirmed that Smiths Detection’s BioFlash can detect down to an estimated 6,000 airborne infectious particles of the SARS-CoV-2 virus within a controlled environment. This compares to as many as one million particles emitted in a single sneeze by a person infected with SARS-CoV-2. The test results also indicate no cross-reactivity with influenza and Middle East Respiratory Syndrome (MERS), an important consideration for environmental monitoring of the SARS-CoV-2 virus.
Further testing and research is underway at a number of US universities to collect more data on how the detection technology can help prevent outbreaks and guide both public and private organizations in COVID-19 mitigation strategies.
About BioFlash Biological Identifier
The BioFlash® Biological Identifier is a bio-aerosol collection and identification system that provides rapid, sensitive and specific identification of various pathogens including viruses, toxins and bacteria. The BioFlash has been commercially available for over 10 years and is currently used by US government and commercial clients for a number of applications.
About Smiths Detection
Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for aviation, ports and borders, defence and urban security markets. Our experience and history across more than 40 years at the frontline enables us to deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.
Our goal is simple – to provide security, peace of mind and freedom of movement upon which the world depends.
For more information visit http://www.smithsdetection.com/
About the U.S. Army Medical Research Institute of Infectious Diseases:
For over 50 years, USAMRIID has provided leading-edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to medical solutions – vaccines, drugs, diagnostics, information, and training programmes – that benefit both military personnel and civilians. Established in 1969, the Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency’s Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Development Command. For more information, visit www.usamriid.army.mil
[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.]
Global Communications Manager
+ 44 (0)7384236474
Marketing and Communications Director – Americas
+1 (203) 482 6752
Tom Hufton/Georgina Reeves
+44 (0)20 3727 1000
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Declares Dividend for Second Quarter 20215.5.2021 22:15:00 CEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.77 per share of its common stock, payable on July 6, 2021 to shareholders of record as of June 25, 2021. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20210505006076/en/Contact information Michael DeVeau Chief Investor Relations & Communications Officer 212.708.7164 Mich
Zynga Announces First Quarter 2021 Financial Results5.5.2021 22:05:00 CEST | Press release
Zynga Inc. (Nasdaq: ZNGA) today released financial results for its first quarter ended March 31, 2021 by posting management’s Q1 2021 Quarterly Earnings Letter to its Investor Relations website. Please see the attached Quarterly Earnings Letter or visit http://investor.zynga.com/financial-information/quarterly-results to access the letter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005238/en/ “We are off to an excellent start in 2021 with record Q1 results driven by breakout performances from our live services, new games and hyper-casual portfolio,” said Frank Gibeau, Chief Executive Officer at Zynga. “Today, we announced our intent to acquire Chartboost, a leading advertising and monetization platform. This transformational acquisition will combine Zynga’s high-quality games portfolio and first-party data with Chartboost’s proven advertising and monetization platform to create a new level of audience scale and mea
Zynga Enters Agreement to Acquire Chartboost5.5.2021 22:05:00 CEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced it has entered into a definitive agreement to acquire Chartboost, a leading mobile programmatic advertising and monetization platform. Along with its talented team, Chartboost brings a global audience of more than 700 million monthly users and more than 90 billion monthly advertising auctions. Together, Zynga and Chartboost possess all the elements of a complete, next generation platform: high-quality content, direct player relationships, massive reach and full-stack advertising technology that can be applied across Zynga’s game portfolio and Chartboost’s advertising partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005033/en/ Zynga Enters Agreement to Acquire Chartboost Chartboost is a unified advertising platform that includes a Demand Side Platform (DSP) as well as Supply Side Platform (SSP) and mediation capabilities del
Altasciences Acquires Calvert Laboratories5.5.2021 18:59:00 CEST | Press release
Altasciences, a forward-thinking CRO/CDMO supporting all crucial steps in early-stage drug development, from lead candidate selection to clinical proof of concept, announced today that they have completed the acquisition of Calvert Laboratories, a preclinical CRO located on the U.S.A.’s East Coast. This acquisition will complement Altasciences’ current preclinical West Coast operations, located just north of Seattle, WA. For more than 40 years, Calvert Laboratories has been working with clients to help develop the next generation of therapeutics aimed at extending and improving human life; in line with Altasciences’ focus on getting better drugs to the people who need them faster. “This acquisition will increase small molecule expertise as well as add efficacy pharmacology, ophthalmology, and carcinogenicity study capabilities, to Altasciences’ current preclinical offering. Furthermore, it expands Altasciences’ presence on the East Coast, and the site is conveniently located in close p
RMS Global Catastrophe Model Leader Launches First Climate Change Models, Enabling New Risk Insights5.5.2021 17:14:00 CEST | Press release
RMS, the world’s leading catastrophe risk modeling and solutions company, revealed that according to its new Climate Change Models, and based on today’s exposures, insured average annual losses (AAL) from North Atlantic Hurricane wind could increase by as much as 24 percent by 2050*, and European Flood risk AAL could increase by up to 59 percent by 2050**, based on no mitigating factors taken. The new RMS Climate Change Models combine the RMS financial impact modeling framework with the best climate science consensus, including from the Intergovernmental Panel on Climate Change (IPCC). Generally available in June 2021, these models provide the most comprehensive climate change insights for North Atlantic Hurricane, Europe Inland Flood, and Europe Windstorm. Each model quantifies and differentiates the impacts of acute physical risk due to variable potential climate change scenarios (known as Representative Concentration Pathways or RCPs), different time horizons, and within specific re
Nel ASA: Receives Purchase Order for 2 MW PEM Electrolyser5.5.2021 16:46:00 CEST | Press release
Nel Hydrogen Electrolyser, a division of Nel ASA (Nel, OSE:NEL), received a purchase order for a 2 MW, fully containerized MC400 electrolyser from H2 Energy. "This is a new milestone achieved in the development of a commercial green hydrogen infrastructure, clearly showing that hydrogen for heavy duty vehicles is a reality today. We are proud that our compact PEM containerized solution has been selected for this second site to supply the refueling stations network," says Raymond Schmid, VP Sales and Marketing EMEA, Nel Hydrogen Electrolyser. The 2 MW PEM electrolyser is the second system to be delivered as part of the green hydrogen infrastructure network that is currently supplying hydrogen to the first 46 Hyundai trucks already operating in Switzerland and aiming to reach a fleet of 1,600 by 2025. The system will be filling 350 barg trailers directly at site to dispatch the hydrogen to the Hydrospider network in Switzerland. H2 Energy is working together with various partners to esta
Sevan Multi-Site Solutions Celebrates 10 Years5.5.2021 15:00:00 CEST | Press release
Sevan Multi-Site Solutions, Inc. (Sevan)—a global leader in innovative design, program management, construction services and data analytics—is excited to celebrate its 10th anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005438/en/ Sevan Multi-Site Solutions celebrates its 10th Anniversary. (Graphic: Business Wire) For a decade, Sevan has committed to providing multi-site solutions for dozens of clients along entire project life cycles. Sevan stays true to the values and core principles it was founded on: Integrity, Respect, Teamwork, Excellence and Charity. Since its inception, Sevan’s entrepreneurial spirit has been accompanied by a culture that is innovative, respectful, inclusive and progressive. “What a joy it has been to work with marvelous people over the last decade while we grew our business,” Jim Evans, President and CEO said. “Thanks so much to our clients, business partners and Sevan team member
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom